Haematological Malignancy
Clinical research at University Hospitals Plymouth NHS Trust is focused on mantle cell lymphoma, a form of non-Hodgkin lymphoma affecting the lymphatic system. The trial portfolio centres on treatment strategies for older patients with untreated disease.
- Mantle Cell Lymphoma
- Non-Hodgkin Lymphoma
- Lymphatic System
- Older Patients
Research activity in this area is directed toward improving outcomes in blood cancer care, with attention to disease control and treatment selection in a specialist oncology setting.
Targeted Oncology Treatment
The sponsored study reflects an interest in targeted therapy and immunotherapy approaches for lymphoma, including the use of Rituximab and Ibrutinib within treatment pathways for mantle cell lymphoma.
- Targeted Therapy
- Immunotherapy
- Rituximab
- Ibrutinib
This therapeutic focus places emphasis on modern systemic treatment options used in haematology-oncology practice.
Chemotherapy Comparison
One major area of interest is the comparison of R-Chemo with non-chemotherapy-based regimens in untreated mantle cell lymphoma, highlighting the evaluation of established and emerging treatment approaches in routine cancer care.
- R-Chemo
- Untreated Disease
- Treatment Selection
- Progression-Free Survival
The research landscape includes clinical interest in disease progression, treatment durability, and regimen choice for lymphoma management.
Multicentre Haematology Research
The sponsor participates in collaborative multicentre research across four countries and 16 collaborating sites, supporting clinical investigation in haematology through coordinated patient recruitment and shared specialist expertise.
- Multicentre Research
- Haematology
- International Collaboration
- Patient Recruitment
Its active recruitment profile indicates ongoing involvement in specialist cancer research delivery within the United Kingdom and beyond.
